Investors Investors

Stock Quote

Stock Quote

4:38 PM EDT on Mar 25

Press Releases

Press Releases

All Releases
Apr 02, 2020
NORTH BILLERICA, MA – April 2, 2020 – Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization of innovative diagnostic imaging agents and products, and Progenics Pharmaceuticals,
Mar 13, 2020
NEW YORK, March 13, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the fourth quarter and full-year 2019. “The recent positive top line results from the Phase 3 CONDOR trial of PyL™ highlights the potential of our radiopharmaceutical
Feb 20, 2020
Combination to Create Robust Portfolio and Pipeline of Precision Diagnostic and Therapeutic Products Progenics Shareholders Will Receive 0.31 Shares of Lantheus Common Stock for Each Share of Progenics Stock in All-Stock Transaction, Represents Approximately 40% Ownership Stake in Combined Company
Feb 06, 2020
NEW YORK, Feb. 06, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that three abstracts highlighting PyL TM ( 18 F-DCFPyL), I-131 1095,
Jan 21, 2020
NEW YORK, Jan. 21, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, issued the following letter to shareholders: January 21,
Jan 16, 2020
NEW YORK, Jan. 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that an abstract highlighting data from its PSMA AI program has been
Dec 23, 2019
- Met Primary Endpoint With a Correct Localization Rate of 84.8–87.0%, Highlighting Strong Diagnostic Performance - Company Expects to Submit an NDA to the FDA in the Second Half of 2020 - Conference Call at 8:00 AM Eastern Time NEW YORK, Dec. 23, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals,
Dec 22, 2019
NEW YORK, Dec. 22, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it will host a conference call to review the top line results
Nov 25, 2019
NEW YORK, Nov. 25, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that four abstracts highlighting PyL (¹⁸F-DCFPyL) have been selected
Nov 21, 2019
NEW YORK, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced its Board of Directors has appointed David W.
Nov 08, 2019
NEW YORK, Nov. 08, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) (“Progenics” or the “Company”), an oncology company developing innovative targeted medicines and artificial intelligence to find, fight and follow cancer, today announced that it has delivered all consents and
Nov 07, 2019
Lantheus Holdings, Inc. to Acquire Progenics to Form an Innovative Commercial Life Sciences Company with a Diversified Portfolio of Precision Diagnostics and Radiopharmaceutical Therapeutics AZEDRA Commercial Dosing Progresses in U.S. as New Technology Add-On Payment Became Effective October 1st;
Nov 06, 2019
Warns Shareholders to Ignore Earlier and Illusory Consent Cutoff Set by Velan Urges Shareholders to Review the S-4 Filing that Will be Made the Week of November 11 about the Value Maximizing Lantheus Transaction in Order to Make a Fully Informed Final Decision about the Consent Solicitation and
Nov 04, 2019
November 17 is the Only Deadline for Velan’s Consent Solicitation Reminds Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 NEW YORK, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc.
Nov 01, 2019
Notifies Shareholders that the S-4 Filing on the Value Maximizing Lantheus Transaction will be Filed with the SEC Before November 17 Shareholders Should Ignore Any Earlier Dates to Deliver Consents Demanded by Velan Urges Shareholders to Review the S-4 Filing in Order to Make Fully Informed Final
Oct 28, 2019
ISS Recognizes that Shareholders Should Have Full Information About the Lantheus Transaction Before Making Significant Decisions About the Company Progenics Urges Shareholders to Protect the Value of Their Investment by Revoking Consent to ALL of Velan’s Proposals NEW YORK, Oct.
Oct 23, 2019
Flags Velan’s Knowledge of Lantheus Transaction Weeks Before It Was Made Public Raises Significant Concerns About Velan’s Questionable Securities Trading, Governance and Ethical Practices Asks Velan’s Nominees if They Want to Be Associated with These Questionable Practices Reminds Shareholders to
Oct 21, 2019
Calls Out Velan’s Pattern of Disregard for Good Corporate Governance and Business Ethics Reminds Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card NEW YORK, Oct. 21, 2019 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX), an oncology company developing
Oct 09, 2019
Highlights Clear and Compelling Value of Lantheus Transaction to All Shareholders Urges Shareholders to Prevent Velan and its Nominees from Seizing Control of the Board and Company without a Premium to All Shareholders Urges Shareholders to Sign and Return Progenics’ WHITE Consent Revocation Card
Oct 02, 2019
Highly Complementary Portfolio of Ultrasound and Radiopharmaceutical Diagnostics and Oncology Therapeutics Lantheus’ Proven Commercial, Manufacturing and Operational Excellence Well Positioned to Optimize the Combined Company’s Innovative Diagnostic and Radiopharmaceutical Portfolio Progenics